Patents by Inventor Michael Eck

Michael Eck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11311357
    Abstract: A polymerizable dental composite material comprising (i) 70 to 85% by weight of an inorganic filler component comprising at least one dental glass and optionally at least one amorphous metal oxide, (ii) 10 to 30% by weight of a mixture of at least two different urethane (meth)acrylates, (iii) 0.01 to 5% by weight of at least one di-, tri-, tetra- or multi-functional monomer not being a urethane (meth)acrylate, (iv) 0.01 to 10% by weight of at least one initiator, of an initiator system as well as optionally of at least one stabilizer and optionally of at least one pigment, wherein the total composition of the composite material amounts to 100% by weight, as well as a polymerized composite material having a flexural strength of greater than or equal to 200 MPa and an elastic modulus of 15 to 20 GPa for producing indirect dentures.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: April 26, 2022
    Assignee: KULZER GMBH
    Inventors: Andreas Utterodt, Kurt Reischl, Nelli Schönhof, Michael Eck, Raif Kocoglu, Jutta Schneider, Caroline Kempka
  • Publication number: 20220106310
    Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.
    Type: Application
    Filed: October 20, 2021
    Publication date: April 7, 2022
    Inventors: John M. Hatcher, Nathanael S. Gray, Jaebong Jang, Dries De Clercq, Pasi Janne, Jamie A. Saxon, Michael Eck, David A. Scott, Alyssa Verano
  • Patent number: 11234904
    Abstract: A polymerisable dental composite material comprising (i) 70 to 85% by weight of an inorganic filler component comprising at least one dental glass and optionally at least one amorphous metal oxide, (ii) 10 to 30% by weight of at least one monomer comprising 1,3-bis(5?-alkyl-3?,8?-dioxo-2?-aza-4?,7?-dioxa-decyl-9?-en)phenyl and/or 1,3-bis(5?,9?-dialkyl-3?,8?-dioxo-2?-aza-4?,7?-dioxa-decyl-9?-en)phenyl, (iii) 0.01 to 5% by weight of at least one di-, tri-, tetra- or multi-functional monomer not being a urethane (meth)acrylate, (iv) 0.01 to 10% by weight of at least one initiator, of an initiator system and optionally of at least one stabilizer and optionally of at least one pigment, wherein the total composition of the composite material amounts to 100% by weight, and a polymerized composite material having a flexural strength of greater than or equal to 190 MPa and an elastic modulus of 12 to 21 GPa for the production of indirect dentures.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: February 1, 2022
    Assignee: KULZER GMBH
    Inventors: Andreas Utterodt, Kurt Reischl, Nelli Schönhof, Michael Eck, Raif Kocoglu, Jutta Schneider, Caroline Kempka
  • Publication number: 20220017510
    Abstract: The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 20, 2022
    Inventors: NATHANAEL S. GRAY, JAEBONG JANG, DRIES DE CLERCQ, MICHAEL ECK, PASI JANNE
  • Patent number: 11219505
    Abstract: A polymerisable dental composite material comprising (i) 70 to 85% by weight of an inorganic filler component comprising at least one dental glass and optionally at least one amorphous metal oxide, (ii) 10 to 30% by weight of a mixture of at least two different urethane(meth)acrylates, (iii) 0.01 to 5% by weight of at least one di-, tri-, tetra- or multi-functional monomer not being a urethane(meth)acrylate, (iv) 0.01 to 10% by weight of at least one initiator, of an initiator system and optionally of at least one stabilizer and optionally of at least one pigment, wherein the total composition of the composite material amounts to 100% by weight, as well as a polymerized composite material having a flexural strength of greater than or equal to 200 MPa and an elastic modulus of 15 to 20 GPa for the production of indirect dentures.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: January 11, 2022
    Assignee: Kulzer GmbH
    Inventors: Andreas Utterodt, Kurt Reischl, Nelli Schönhof, Michael Eck, Raif Kocoglu, Jutta Schneider, Caroline Kempka
  • Patent number: 11186574
    Abstract: The application relates to a compound having Formula X: which modulates the activity of HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which HER2 and/or a mutant thereof, and/or EGFR and/or a mutant thereof, plays a role.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: November 30, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: John M. Hatcher, Nathanael S. Gray, Jaebong Jang, Dries De Clercq, Pasi Janne, Jamie A. Saxon, Michael Eck, David A. Scott, Alyssa Verano
  • Patent number: 11161842
    Abstract: The present application provides bifunctional compounds of Formula (I): which act as protein degradation inducing moieties for EGFR and/or a mutant thereof. The present application also describes methods for the targeted degradation of EGFR and/or a mutant thereof through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to EGFR and/or a mutant thereof which can be utilized in the treatment of disorders modulated by EGFR or a mutant thereof.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: November 2, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Nathanael Gray, Jaebong Jang, Dries De Clercq, Michael Eck, Pasi Janne
  • Publication number: 20210169608
    Abstract: Disclosed is a two-component mixing capsule for intake and for mixing of two compositions with a capsule housing having a discharge spout at its front end, wherein the mixing capsule comprises a first mixing chamber and a second mixing chamber, wherein the two mixing chambers may be separated from each other for storage or for transport, by the first mixing chamber being rotatable into a first position in which the first mixing chamber is separated from mixing chamber, by a rotatably mounted handhold element, the rotational axis of which is approximately perpendicularly arranged to the longitudinal axis of the mixing capsule. The two mixing chambers form a common mixing chamber by rotating the first mixing chamber into a second position in which the central axes of the first and second mixing chamber are substantially coaxially arranged, wherein the composition may be discharged after mixing by attaching a squeezing piston.
    Type: Application
    Filed: May 24, 2018
    Publication date: June 10, 2021
    Applicant: KULZER GMBH
    Inventors: Andrea KEMENY, Mike KONDZIELA, Ralf SUFFEL, Andreas UTTERODT, Michael ECK, Raif KOCOGLU, Markus BALKENHOL
  • Publication number: 20210094913
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: September 28, 2020
    Publication date: April 1, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. GRAY, Michael ECK, Pasi JANNE, Hwan Geun CHOI, Jaebong JANG, Kwok-Kin WONG
  • Publication number: 20210085688
    Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: March 25, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK
  • Publication number: 20210077469
    Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: (I?), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: March 18, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Publication number: 20210040088
    Abstract: The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: February 11, 2021
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Publication number: 20200390783
    Abstract: The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 17, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Publication number: 20200377501
    Abstract: The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Publication number: 20200377477
    Abstract: The application relates to a compound having Formula (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a N pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Publication number: 20200375999
    Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: (I?), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: NATHANAEL S. GRAY, DRIES DE CLERCQ, JAEBONG JANG, PASI JANNE, CIRIC TO, MICHAEL ECK, EUNYOUNG PARK, DAVID HEPPNER
  • Patent number: 10836722
    Abstract: The disclosure relates to a compound having Formula (I?): and in particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: November 17, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Michael Eck, Pasi Janne, Hwan Geun Choi, Jaebong Jang, Kwok-Kin Wong
  • Publication number: 20200315925
    Abstract: A polymerisable dental composite material comprising (i) 70 to 85% by weight of an inorganic filler component comprising at least one dental glass and optionally at least one amorphous metal oxide, (ii) 10 to 30% by weight of at least one monomer comprising 1,3-bis(5?-alkyl-3?,8?-dioxo-2?-aza-4?,7?-dioxa-decyl-9?-en)phenyl and/or 1,3-bis(5?,9?-dialkyl-3?,8?-dioxo-2?-aza-4?,7?-dioxa-decyl-9?-en)phenyl, (iii) 0.01 to 5% by weight of at least one di-, tri-, tetra- or multi-functional monomer not being a urethane (meth)acrylate, (iv) 0.01 to 10% by weight of at least one initiator, of an initiator system and optionally of at least one stabilizer and optionally of at least one pigment, wherein the total composition of the composite material amounts to 100% by weight, and a polymerized composite material having a flexural strength of greater than or equal to 190 MPa and an elastic modulus of 12 to 21 GPa for the production of indirect dentures.
    Type: Application
    Filed: October 1, 2018
    Publication date: October 8, 2020
    Applicant: KULZER GMBH
    Inventors: Andreas UTTERODT, Kurt REISCHL, Nelli SCHÖNHOF, Michael ECK, Raif KOCOGLU, Julta SCHNEIDER, Caroline KEMPKA
  • Publication number: 20200253836
    Abstract: A polymerisable dental composite material comprising (i) 60 to 85% by weight of an inorganic filler component comprising at least one tectosilicate and optionally at least one dental glass and/or at least one amorphous metal oxide, (ii) 10 to 40% by weight of a mixture of at least two different urethane(meth)acrylates, (iii) 0.01 to 5% by weight of at least one di-, tri-, tetra- or multi-functional monomer not being a urethane(meth)acrylate, (iv) 0.01 to 10% by weight of at least one initiator, an initiator system and optionally at least one stabiliser and optionally at least one pigment, wherein the total composition of the composite material amounts to 100% by weight, and a polymerised composite material having a flexural strength of greater than or equal to 240 MPa and an elastic modulus of 16 to 20 GPa for the production of indirect dentures.
    Type: Application
    Filed: October 1, 2018
    Publication date: August 13, 2020
    Applicant: KULZER GMBH
    Inventors: Andreas UTTERODT, Kurt REISCHL, Nelli SCHÖNHOF, Michael ECK, Raif KOCOGLU, Julta SCHNEIDER, Caroline KEMPKA
  • Publication number: 20200253691
    Abstract: A polymerisable dental composite material comprising (i) 70 to 85% by weight of an inorganic filler component comprising at least one dental glass and optionally at least one amorphous metal oxide, (ii) 10 to 30% by weight of a mixture of at least two different urethane (meth)acrylates, (iii) 0.01 to 5% by weight of at least one di-, tri-, tetra- or multi-functional monomer not being a urethane (meth)acrylate, (iv) 0.01 to 10% by weight of at least one initiator, of an initiator system and optionally of at least one stabilizer and optionally of at least one pigment, wherein the total composition of the composite material amounts to 100% by weight, as well as a polymerized composite material having a flexural strength of greater than or equal to 200 MPa and an elastic modulus of 15 to 20 GPa for the production of indirect dentures.
    Type: Application
    Filed: October 1, 2018
    Publication date: August 13, 2020
    Applicant: KULZER GMBH
    Inventors: Andreas UTTERODT, Kurt REISCHL, Nelli SCHÖNHOF, Michael ECK, Raif KOCOGLU, Jutta SCHNEIDER, Caroline KEMPKA